- Home
- TLSI vs PRME Comparison
TLSI vs PRME Comparison
Compare TLSI & PRME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TLSI
- PRME
- Stock Information
- Founded
- TLSI 2010
- PRME 2019
- Country
- TLSI United States
- PRME United States
- Employees
- TLSI N/A
- PRME N/A
- Industry
- TLSI Medical Specialities
- PRME Medicinal Chemicals and Botanical Products
- Sector
- TLSI Health Care
- PRME Health Care
- Exchange
- TLSI Nasdaq
- PRME Nasdaq
- Market Cap
- TLSI 204.0M
- PRME 191.7M
- IPO Year
- TLSI N/A
- PRME 2022
- Fundamental
- Price
- TLSI $4.56
- PRME $4.21
- Analyst Decision
- TLSI Strong Buy
- PRME Buy
- Analyst Count
- TLSI 5
- PRME 6
- Target Price
- TLSI $10.90
- PRME $9.38
- AVG Volume (30 Days)
- TLSI 134.8K
- PRME 5.8M
- Earning Date
- TLSI 08-13-2025
- PRME 08-04-2025
- Dividend Yield
- TLSI N/A
- PRME N/A
- EPS Growth
- TLSI N/A
- PRME N/A
- EPS
- TLSI N/A
- PRME N/A
- Revenue
- TLSI $32,141,000.00
- PRME $3,846,000.00
- Revenue This Year
- TLSI $55.39
- PRME $104.12
- Revenue Next Year
- TLSI $54.89
- PRME $108.24
- P/E Ratio
- TLSI N/A
- PRME N/A
- Revenue Growth
- TLSI 46.20
- PRME 550.76
- 52 Week Low
- TLSI $3.50
- PRME $1.11
- 52 Week High
- TLSI $6.04
- PRME $5.95
- Technical
- Relative Strength Index (RSI)
- TLSI 39.21
- PRME 60.42
- Support Level
- TLSI $4.41
- PRME $3.71
- Resistance Level
- TLSI $4.73
- PRME $5.15
- Average True Range (ATR)
- TLSI 0.22
- PRME 0.53
- MACD
- TLSI -0.02
- PRME -0.06
- Stochastic Oscillator
- TLSI 18.99
- PRME 34.25
About TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product linesPressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.
About PRME Prime Medicine Inc.
Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome and can treat a wide spectrum of diseases with high unmet medical needs and efficient and broad gene editing technology.